Clinical Trial Update: Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing G-CSF alone to intermediate-dose Ara-C plus G-CSF mobilization in multiple myeloma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ara-C (cytarabine)
• G-CSF (granulocyte colony-stimulating factor)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED